Aldeyra Therapeutics, Inc. (ALDX)
| Previous Close | 5.40 |
| Open | 5.39 |
| Bid | 3.81 x 200 |
| Ask | 5.44 x 100 |
| Day's Range | 5.24 - 5.50 |
| 52 Week Range | 2.20 - 6.55 |
| Volume | |
| Avg. Volume | 544,935 |
| Market Cap | 323.254M |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | Nov 04, 2024 - Nov 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.29 |
- Business Wire
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
LEXINGTON, Mass., October 31, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024.
- Business Wire
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass., October 03, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmission includes pr
